Compile Data Set for Download or QSAR
Report error Found 108 Enz. Inhib. hit(s) with all data for entry = 1242
TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313715(US10167280, Example 20 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 3.10nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313704(US10167280, Example 9 | US10167280, Example 44 | U...)
Affinity DataIC50: 4nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313714(US10167280, Example 19 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 4.30nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313714(US10167280, Example 19 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 4.60nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313723(US10167280, Example 28 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 4.60nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313715(US10167280, Example 20 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 5.10nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313721(US10167280, Example 26 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 5.60nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313719(US10167280, Example 24 | US10167280, Example 25 | ...)
Affinity DataIC50: 5.70nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313704(US10167280, Example 9 | US10167280, Example 44 | U...)
Affinity DataIC50: 5.80nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313712(US10167280, Example 17 | US10167280, Example 22)
Affinity DataIC50: 6nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313703(US10167280, Example 8)
Affinity DataIC50: 6nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313719(US10167280, Example 24 | US10167280, Example 25 | ...)
Affinity DataIC50: 6.20nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313721(US10167280, Example 26 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 6.20nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313712(US10167280, Example 17 | US10167280, Example 22)
Affinity DataIC50: 6.5nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313721(US10167280, Example 26 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 6.90nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313701(US10167280, Example 6 | US10167280, Example 23)
Affinity DataIC50: 7nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313701(US10167280, Example 6 | US10167280, Example 23)
Affinity DataIC50: 7.10nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313719(US10167280, Example 24 | US10167280, Example 25 | ...)
Affinity DataIC50: 7.40nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313721(US10167280, Example 26 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 8nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313704(US10167280, Example 9 | US10167280, Example 44 | U...)
Affinity DataIC50: 8nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313724(US10167280, Example 29 | 5-({2-[4-(2-Cyano-5-methy...)
Affinity DataIC50: 8.20nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313723(US10167280, Example 28 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 8.60nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313719(US10167280, Example 24 | US10167280, Example 25 | ...)
Affinity DataIC50: 8.60nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313704(US10167280, Example 9 | US10167280, Example 44 | U...)
Affinity DataIC50: 9nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313724(US10167280, Example 29 | 5-({2-[4-(2-Cyano-5-methy...)
Affinity DataIC50: 10nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313703(US10167280, Example 8)
Affinity DataIC50: 11nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313726(US10167280, Example 31 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 11nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313727(US10167280, Example 32 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 11nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313700(US10167280, Example 5)
Affinity DataIC50: 12nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313727(US10167280, Example 32 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 12nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313728(US10167280, Example 33 | 5-({2-[4-(2-Cyano-5-methy...)
Affinity DataIC50: 14nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313731(US10167280, Example 36 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 14nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313732(US10167280, Example 37 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 14nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313699(US10167280, Example 4)
Affinity DataIC50: 16nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313697(US10167280, Example 2)
Affinity DataIC50: 16nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313733(US10167280, Example 38 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 16nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313725(US10167280, Example 30 | 5-({2-[4-(2-Cyano-5-methy...)
Affinity DataIC50: 17nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313730(US10167280, Example 35 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 19nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313731(US10167280, Example 36 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 19nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313728(US10167280, Example 33 | 5-({2-[4-(2-Cyano-5-methy...)
Affinity DataIC50: 19nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313696(US10167280, Example 1)
Affinity DataIC50: 20nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313697(US10167280, Example 2)
Affinity DataIC50: 20nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313701(US10167280, Example 6 | US10167280, Example 23)
Affinity DataIC50: 20nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313725(US10167280, Example 30 | 5-({2-[4-(2-Cyano-5-methy...)
Affinity DataIC50: 20nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313712(US10167280, Example 17 | US10167280, Example 22)
Affinity DataIC50: 22nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313696(US10167280, Example 1)
Affinity DataIC50: 22nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313701(US10167280, Example 6 | US10167280, Example 23)
Affinity DataIC50: 22nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313710(US10167280, Example 15)
Affinity DataIC50: 23nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313732(US10167280, Example 37 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 23nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313733(US10167280, Example 38 | 5-({2-[4-(5-Chloro-2-cyan...)
Affinity DataIC50: 23nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 108 total ) | Next | Last >>
Jump to: